FDA
Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL
Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the…
Tag
Roche
3 stories
Deals
Paid $20M Upfront, Roche Extends C4T Molecular Glue Deal
Roche is paying $20 million upfront for access to two degrader-antibody conjugate (DAC) programs from C4 Therapeutics, with more than $1 billion in…
Deals
Gilead Pays $3.15B for Tubulis in Third ADC Bet of 2026
Gilead's $3.15B upfront buy of Tubulis adds a 59%-ORR NaPi2b ADC to its pipeline — its third acquisition of 2026, totaling over $12B spent.
